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In this study we demonstrate for the first time that GSH could rapidly conjugate with dopamine 
(DA)-derived DA-o-quinones without enzymatic catalysis to form short-lived intermediate GSH-
conjugates (2-S-GSH-DA-o-quinone and 5-S-GSH-DA-o-quinone). These intermediate GSH-
conjugates are unstable and would finally form reactive or non-reactive GSH-conjugates 
dependent on ambient reductive forces. Under insufficient reductive forces, the intermediate 
GSH-conjugates could cyclize spontaneously to form reactive 7-S-GSH-aminochrome (7-S-GSH-
AM).  The 7-S-GSH-AM is so reactive that it could further react with another GSH to form 4,7-
bi-GSH-5,6-dihydroindole.  Its reactivity could also abrogate tyrosinase activity in solutions.  In 
addition, the 7-S-GSH-AM could further undergo internal rearrangement to form non-reactive 7-
S-GSH-5,6-dihydroindole. From these novel findings, we propose two detrimental positive 
feedback loops involving accelerated DA oxidation, increased GSH consumption and impaired 
GSH detoxification efficiency, as the underlying chemical explanation for dopaminergic neuron 












Parkinson’s disease (PD), characterized by tremor, rigidity, postural instability, and bradykinesia, 
is the most common serious movement disorder in the world, affecting about 1% of adults older 
than 60 years 1.  The dopamine (DA) related oxidative stress was suggested to be the key event in 
the genesis of PD 2.  DA oxidation could produce reactive oxygen species (ROS) and reactive DA 
quinones 3.  The ROS could lead to comprehensive damage including proteins, lipids and nucleic 
acids in cells 4.  On the other hand, DA quinones are highly reactive and could covalently react 
with the cysteine residues of functional proteins and irreversibly inhibit their activity 5, 6.  The 
highly reactive DA-derived DA quinones rather than ROS have been suggested to play an 
important role in DA-induced toxicity related to PD pathogenesis 7-9.  Various studies have shown 
that DA-derived DA quinones could impair mitochondria contributing to dopaminergic neuron 
demise 10-12. Our previous study has also demonstrated that DA could induce irreversible 
proteasome inhibition via DA-derived quinones rather than via the ROS 13.  
 
To date, GSH has been implicated to be an important endogenous protective factor against 
the toxicity of DA 14, 15.  GSH could detoxify DA-related toxicity through conjugation with DA-
derived quinones, besides scavenging ROS 16, 17.   In the presence of GSH transferase, GSH could 
conjugate with DA-derived quinone to form 5-S-GSH-DA 16.  Furthermore GSH transferase 
could catalyze GSH conjugation with AM to form 4-S-GSH-5,6-dihydroxyindoline 17.  In our 
recent study using an improved tandem HPLC procedure coupled with ESI-MS, we found that 
GSH could actually react with AM to form various GSH conjugates without any enzymatic 
catalysis 18.  We have also shown in a separate study that DA-derived quinones are associated 
with cellular toxicity induced by mutant alpha-synuclein which is associated strongly with PD 19.   
Meanwhile, other investigators have reported that intrastriatal injection or administering of DA 
could significantly decrease GSH level in the brain of experimental animals as well as in cultured 
astroglial cells 20, 21.  In addition, postmortem studies have implicated the decrease of GSH level 
in the substantia nigra (SN) of the brain to be the early event for PD onset since there was an 
obvious decrease (~ 40 %) of GSH in the SN of early and advanced PD patients compared with 
the aged controls 22, 23.  Furthermore, when compared with aged controls, the highest level of 
GSH-DA conjugates were detected in the SN and putamen of postmortem PD patients 24.  Taken 
together, these observations inferred that the increased production of DA-derived quinones and 
consumption of GSH via conjugation between GSH and DA-derived quinones are vital events 
highly related to PD.   
 
In this study, we report for the first time that GSH could rapidly conjugate with DA-derived 
quinones to form reactive or non-reactive GSH conjugates dependent on ambient reductive force 
and without any enzymatic catalysis.  Based on our findings, two detrimental positive feedback 
loops leading to an imbalance between DA oxidation and GSH protective capacity are proposed 
to help us understand the chemical explanation underlying DA neuron degeneration. These 
detrimental feedback loops may act together in a vicious cycle aggravating GSH decrease in the 




Our first set of analysis was to characterize the DA quinones derived from DA oxidation under 
different conditions as well as their conjugation with GSH. Our experimental data revealed that 
after DA was catalyzed by tyrosinase in the absence of GSH, AM could be detected and it 
surfaced as a peak in our HPLC A chromatogram (Fig. 1a).  However in the presence of GSH, 
the formation of AM was abrogated and new peaks corresponding to conjugates between GSH 
and DA-derived quinones emerged (Fig. 1b – f; 1h). We named these new peaks as p1, p2, p3 
and p4 according to their retention time in the HPLC chromatogram: p1 = 2.30 min; p2 = 4.10 
min; p3 = 4.65 min and p4 = 8.85 min (Fig. 1b - f).  In our previous study we had demonstrated 
that the compound corresponding to p1 was the polymerized form of GSH conjugates 18.  The p3 
resembled AM in its profile, which had light absorbance at 280, 375 and 475 nm wavelengths in 
the HPLC A chromatogram, as well as two light absorbance peaks at about 280 and 475 nm 
wavelengths in the light absorbance spectrometry; whereas p2 and p4 only had light absorbance 
at 280 nm wavelength (Fig. 1b – d, 1m).  Furthermore we found that the formation of GSH-DA 
quinone conjugates was GSH concentration dependent; with higher concentration of GSH  
leading to p2 and p4 formation, while lower concentration of GSH leading to p1 and p3 formation 
(Fig. 1).   
 
To better understand the nature of p1, p2, p3, and p4, we carefully analyzed their profiles of 
peak area changes in the chromatograms. Detailed changes in the area of the respective peaks 
after 1 mM DA had been catalyzed by 0 - 200 unit tyrosinase for 20 min in the presence of 0.2 - 8 
mM GSH are illustrated in Figures 1g - l.  We found that p1 and p3 emerged when the lowest 
GSH concentration (0.2 mM) was applied and reached their highest level when GSH 
concentration was about 0.5 mM, but began to decrease with further increase in GSH 
concentration (Fig. 1i, k). Interestingly, p1 and p3 would completely disappear when GSH 
concentration was more than 1.5 mM (Fig. 1i, k).  On the other hand, p2 and p4 began to emerge 
when GSH concentration was more than 0.5 mM.  The peak areas of p2 and p4 increased 
proportionally to GSH concentration till GSH concentration was about less than 1.5 mM, but 
decreased when GSH concentration was more than 1.5 mM (Fig. 1j, l).  The peak area of p4 was 
higher than that of p2, suggesting that the formation of p4 was more rapid than that of p2.   
 
We also found that there was a curvilinear tendency in the change of DA peak areas after DA 
was catalyzed by 100 or 200 unit tyrosinase in the presence of different concentration of GSH 
(Fig. 1g). We observed that the changes in peak areas of p3 (Fig. 1k) were closely synchronizing 
with that of DA peak areas changes (Fig. 1g) when GSH concentration was in the range of 0 – 1.5 
mM (200 unit tyrosinase) or 0 – 1.0 mM (100 unit tyrosinase).  The p3 and DA peak areas 
increased to a maximum when GSH concentration was 0.5 mM but decreased with GSH 
concentration further increase (0.5 – 1.5 mM (200 unit tyrosinase) or 0.5 – 1.0 mM (100 unit 
tyrosinase)) (Fig. 1g, k).  Since higher DA peak areas were indications of decreased tyrosinase 
activity, and they synchronized with the profile changes in p3, therefore p3 was implicated to 
cause tyrosinase inhibition when GSH concentration was in the range of 0.2 – 1.0 or 1.5 mM. The 
DA peak areas decreased to the lowest level when GSH concentration was 1.0 mM (100 unit 
tyrosinase) or 1.5 mM (200 unit tyrosinase), and since in this concentration range p3 was absent, 
tyrosinase activity was not inhibited and hence DA oxidation could proceed (Fig. 1g). However 
when GSH concentration was further increased to the range of 2 – 8 mM, there was a 
corresponding gradual increase in DA peak areas (Fig. 1k).  Under such high concentration of 
GSH, the tyrosinase inhibition in the absence of p3 should be due to direct effect of GSH since in 
our previous studies we have demonstrated that GSH at high concentration could directly inhibit 
tyrosinase-catalyzed DA oxidation 19. The inhibition of tyrosinase by GSH would lead to 
decreased production of DA-o-quiones and thereby decrease p2 and p4 formation accordingly, 
although high GSH concentration would favor p2 and p4 formation and disfavor p3 formation 
(Fig. 1g, j, k, l).   
 
To further understand the nature of p1, p2, p3 and p4 we studied the conjugations between 
DA-quinones and GSH under different reaction time. We found that the formation of GSH-DA 
quinones conjugates were also reaction time dependent (Fig. 2).   We observed that after catalysis 
for 2 – 10 min, only p2 and p4 emerged (Fig. 2a - c).  However, after a longer incubation time 
(20 min or more time) p1, p3 and AM appeared (Fig. 2d – f).  The p1 increased continually while 
p2, p3 and p4 would decline with time after reaching their highest levels.  A logical explanation 
for these observations could be due to spontaneous polymerization of GSH conjugates in 
solutions over time.  Detailed changes in the various peak areas with time in the presence of 0 – 2 
mM GSH are illustrated in Figure 2g – l.   Interestingly, the speed of DA oxidation decelerated 
with time (especially in the presence of 0.5 mM GSH) (Fig. 2g).   After catalysis for 20 min in 
the presence of 0.5 mM GSH or for 240 min in the presence of 1 mM GSH, the peak areas of DA 
were significantly higher than those in the absence of GSH or in the presence of 2 mM GSH (Fig. 
2g).  These intriguing results inferred that tyrosinase was more significantly inhibited in the 
presence of 0.5 or 1 mM GSH than in the absence of GSH or in the presence of 2 mM GSH.  As 
p3 only emerged when GSH concentrations were 0.5 and 1 mM but not in the presence of 2 mM 
GSH, these results implied again that p3 was actually inhibiting tyrosinase.  
 
We next asked what would happen if we modify the ambient reductive forces in the solutions. 
The results showed that the formation of GSH conjugates could be influenced by AA and 
NADPH (Fig. 3). The presence of 1 mM AA or 1 mM NADPH would significantly inhibit p1, p3 
and AM formation but promote p2 and p4 formation (Fig. 3a – c).  The decrease in AM and p3 
peak areas was dependent on the AA and NADPH dosage (Fig. 3g, h, k, l).   However, the 
influence of AA and NADPH concentrations on p4 peak areas (Fig. 3i, m) and on DA peak areas 
(Fig. 3f, j) was observed to be bidirectional but opposite with one another.  The p4 production 
rate was found to increase and then decrease with increasing AA or NADPH concentration after 
an ‘optimal concentration’ of the reductant was applied; whereas the DA peak areas decreased 
and then increased after the optimal reductant concentration was applied.  We propose that the 
lower concentration of AA and NADPH could inhibit AM and p3 production, but promote p2 and 
p4 production, thereby facilitate tyrosinase catalysis and hence lead to decreased DA peak areas. 
On the contrary, the higher concentration of AA and NADPH could directly inhibit tyrosinase 
catalysis as high concentration of GSH would, thereby decrease p4 formation and hence the 
corresponding increase in DA peak areas. 
 
To further understand the chemical nature of conjugation reactions between DA quiones and 
GSH, the reaction solutions were first aerated with or without oxygen and nitrogen gas. In 
principle oxygen is able to receive protons and electrons and form water while nitrogen does not 
have such a property. We discovered that tyrosinase catalyzed oxidation of DA and formation of 
GSH conjugates could be influenced by these gases (Fig. 4).  We showed that when distilled 
water had been aerated with oxygen gas beforehand, p3 and AM peaks increased and DA peak 
decreased significantly while formation of p2 and p4 was abrogated (Fig. 4a, b, d).  However 
when distilled water had been aerated with nitrogen gas beforehand, the reverse situation emerged 
(Fig. 4c, d).  Obviously, oxygen facilitated AM and p3 formation while nitrogen facilitated p2 
and p4 formation.  
 
To identify the respective GSH conjugates, they were subjected to tandem HPLC plus ESI-
MS analysis.  The p2 and p4 were separated and collected from HPLC A procedure (Fig. 5a).   
The pH value of the collected solutions was adjusted to pH 8.0. The solutions were further 
incubated at 37 °C for 3 hrs.  We found that after incubation under a basic pH condition, p2 and 
p4 would both aggregate and transform to p1 (Fig. 5b, e).   Alternatively the collected p2 and p4 
from HPLC A procedure could be further purified through the HPLC B procedure (Fig. 5c, d).   
Peaks for p2 and p4 in HPLC B chromatogram were collected again and underwent ESI-MS 
analysis. We found that the molecular weight (MW) of p2 and p4 were both 458 (m/z = 459) (Fig. 
5f, g). We therefore concluded that p2 and p4 are isomeric compounds and could form via 
conjugation between one GSH and one DA-derived quinone. However, p2 and p4 could not 
further conjugate with GSH in solutions (data not shown).  
 
Similarly, we collected p3 and AM from HPLC A procedure (Fig. 6a).  Interestingly we 
found that p3 could automatically transform into a new GSH conjugate in solutions (Fig. 6b, e). 
This new GSH conjugate only had light absorbance at 280 nm wavelength and had retention time 
of about 9.30 min in HPLC A chromatogram (Fig. 6e).  We named the peak of this new GSH 
conjugate as p6.  Almost all of p3 had transformed into p6 after 3 hr incubation (Fig. 6e).  We 
also demonstrated that incubation of p3 overnight at 37 °C under basic pH condition could lead to 
decrease of p6 peak areas and p1 formation, suggesting that p6 could also aggregate under basic 
conditions to form p1 (Fig. 6f).  We also found that p6 lost the ability to further react with GSH 
in solutions (data not shown).  However we noticed that p3 was still reactive and could further 
conjugate with another GSH in solutions (Fig. 6c).  After incubating the collected p3 with 2 mM 
GSH for 3 hrs, a new peak emerged before p6 in HPLC A chromatogram, with a retention time of 
about 8.0 min and light absorbance at 280 nm wavelength (Fig. 6c).  We named this new peak p5.   
Simultaneously, we revealed that AM collected from HPLC A could react with GSH to form a 
large peak and a tiny peak (Fig. 6d).   The large peak had retention time of about 9.90 min and 
light absorbance at 280 nm wavelength while the tiny peak was the same as p6 (Fig. 6d, g).  We 
named the new large peak p7.   We later found that p7 also could not react with GSH (data not 
shown).   Subsequently, p3, p5, p6 and p7 collected from HPLC A were further purified through 
HPLC B procedure and analyzed by ESI-MS (Fig. 6h – k).  Interestingly, the MW of p3, p6 and 
p7 were all found to be 454 (Fig. 6h, j, k).   Since p3, p6 and p7 all have the same molecular 
weight of 454, they are isomeric chemicals. The MW of p5 was about 759, corresponding nicely 




In our previous studies, we showed that our new HPLC procedures were suitable to separate DA 
quinones and various GSH-DA quinone conjugates in HPLC chromatogram 18.  With these new 
HPLC procedures we demonstrated, for the first time, that GSH (MW 307) could conjugate with 
DA-o-quinones (MW 151) to form reactive (p3, MW 454) or non-reactive (p2 and p4, MW 458) 
GSH-DA quinone conjugates dependent on the concentration of GSH, reaction time, and the 
presence of ambient reductants, oxygen or nitrogen gas in the solution.  From our previous study 
we learned that the reaction between GSH and DA quinones are condensation reactions 
concomitant with desquamation of two protons and two electrons when each covalent bond 
formed between GSH and DA quinones 18. The experimental results from the current study 
inferred that after desquamation of two protons and electrons, intermediate GSH conjugates (MW 
456) with short life span must have formed at the initial stage of the reaction between GSH and 
DA-o-quinones.  The formation of intermediated GSH conjugates is consistent with recent 
findings that cysteine could react with DA-o-quinone to yield 5-S-cysteine-DA-o-quinone which 
could further transform into 5-S-cysteine-DA 25. The desquamated two protons and electrons 
could be passed on to an oxygen and lead to water formation; or be returned back to the GSH 
conjugates if no oxygen is around.  We learned from the current study that the intermediate GSH 
conjugates (MW 456) is unstable.  It could receive two protons and electrons to form p2 or p4 
when the ambient reductive force is strong.  However when the ambient reductive force is 
insufficient, the intermediate GSH conjugates tend to cyclize to form p3 concomitant with further 
desquamation of two protons and two electrons.  
 
It has been established that GSH could react with DA-o-quinone mainly at the 5th position 
(C5) and secondarily at the 2nd position (C2) to form more 5-S-GSH-DA (MW 458) and minor 2-
S-GSH-DA (MW 458) 16, 25-27.   We therefore deduced that the identity of p2 should be 2-S-GSH-
DA and p4 should be 5-S-GSH-DA.   The intermediate GSH conjugates for 2-S-GSH-DA and 5-
S-GSH-DA should then be 2-S-GSH-DA-o-quinone (MW 456) and 5-S-GSH-DA-o-quinone 
(MW 456) respectively.  The cyclization of 5-S-GSH-DA-o-quinone will form 7-S-GSH-AM 
(MW 454); whereas the cyclization of 2-S-GSH-DA-o-quinone will form 4-S-GSH-AM (MW 
454).   As the product of 5-S-GSH-DA-o-quinone is supposed to be more than that of 2-S-GSH-
DA-o-quinone, the product of cyclic 7-S-GSH-AM would be more than that of 4-S-GSH-AM. 
We hence propose that p3 produced in a large amount should be 7-S-GSH-AM.  However we 
have not observed peaks corresponding to 4-S-GSH-AM derived from 2-S-GSH-DA-o-quinone. 
This might be due to the amount produced for 4-S-GSH-AM is much less than that of 7-S-GSH-
AM.  Furthermore since S-GSH-AM aggregates very fast in solution, the minor amount of 4-S-
GSH-AM would have aggregated and disappeared before detection.  
 
Our previous study has demonstrated that AM could conjugate with GSH in basic solutions 
(pH 7.8) to form 4,7-bi-S-GSH-5,6-dihydroxyindole (MW 759), 7-S-GSH-5,6-dihydroxyindole 
(MW 454), and 4-S-GSH-5,6-dihydroxyindole (MW 454) with retention time and MW 
corresponding to those of p5, p6 and p7 respectively in this study 18.   In the current study, we 
found that AM collected in acidic HPLC elution buffer (pH 4.75) could conjugate with GSH to 
mainly form p7, whereas the product of p6 was minor.  We inferred that the identity of p5 should 
be 4,7-bi-S-GSH-5,6-dihydroxyindole; p6 should be 7-S-GSH-5,6-dihydroxyindole while p7 
should be 4-S-GSH-5,6-dihydroxyindole.  We also demonstrated in the current study that p3 
could automatically transform into p6 (7-S-GSH-5,6-dihydroxyindole) which further supported 
the identity of p3 to be 7-S-GSH-AM.  The previous findings that cyclized AM could undergo 
internal rearrangement to form 5,6-dihydroxyindole coincide with and support our current 
findings that cyclized 7-S-GSH-AM (p3) could rearrange to form 7-S-GSH-5,6-dihydroxyindole 
(p6) 28, 29.  With all the identities of the GSH conjugates and DA quinones put into a logical 
relationship, we can then make sense of the detailed process for GSH conjugates formation which 
is illustrated in Figure 7. 
 
The 7-S-GSH-AM is so reactive that it could conjugate with another GSH and even inhibit 
tyrosinase activity in solutions.  Postmortem studies have shown that there were increased 
conjugates of cysteine or GSH with DA quinones implicating accelerated DA oxidation 
concomitant with obvious decreased (~ 40 %) GSH level in the substantia nigra (SN) of PD 
patients, which were not accompanied by a corresponding increase in glutathione disulfide 
(GSSG) 22-24. Furthermore the decreased GSH level in SN was demonstrated to be the early 
events in the development of the disease 22, 23.   Our unpublished data showed that various iron 
species could trigger DA oxidation in solutions, which could not be inhibited by GSH but could 
be abrogated by iron chelator.  The iron species have been established to be highly implicated for 
PD pathogenesis 30, 31. Taken together, two detrimental positive feedback loops were proposed as 
depicted in Figure 8. They involve accelerated DA oxidation, increased GSH consumption, 
decreased GSH detoxification efficiency and decreased GSH level, which collectively could 
contribute to PD (Fig. 8).  
 
The detrimental positive feedbacks could be triggered by pathological factors, such as iron 
accumulations, which will lead to an accelerated DA oxidation out of the control of GSH.  The 
accelerated DA oxidation could produce DA quinones which could conjugate with GSH leading 
to irreversible depletion of GSH and decreased GSH level in the cells.  The decreased GSH level 
will lead to reactive 7-S-GSH-AM formation which could further react with GSH and thus 
decrease GSH detoxification efficiency for DA quinones. This detrimental effect will lead to 
accelerated GSH consumption and aggravated decrease of GSH level in the cells. At the same 
time, the decreased GSH level will favor DA oxidation and contribute to increased oxidative 
stress and DA quinones production making a double-detriment to the cells.  The ROS produced 
from DA oxidation will deplete endogenous reductants and thereby favor reactive 7-S-GSH-AM 
production.   All these vicious cycle outcomes will lead to an imbalance between DA toxicity and 
GSH protective capacity and finally dopaminergic neuron degeneration. We believe that these 
mechanisms help us understand the chemical basis for PD onset and development. 
 
If our proposed scheme is further validated through future researches, then therapies to 
elevate GSH level in cells; or the use of GSH substitutes with sulphydryl groups which could 
easily penetrate through the blood-brain-barrier; and the administration of exogenous reductants 
may very well function to hinder or break the vicious chemical feedbacks, and therefore benefit 
PD patients.  
 METHODS 
 
Materials. Acetonitril, DA, EDTA, GSH, HEPES, tyrosinase (from mushroom), ascorbic acid 
(AA) and NADPH were all purchased from Sigma (U.S.A.).  
 
The improved HPLC A procedure 17. Our HPLC A procedure used two elution buffer systems 
(elution buffer A and elution buffer B). The elution buffer A was 8 % methanol (v/v), 0.1 M 
sodium phosphate, 20 mM sodium 1-heptane-sulfonate, 0.1 mM EDTA, adjusted to pH 4.75 with 
NaOH, whereas elution buffer B was 80 % (v/v) acetonitril in distilled water.  The improved 
HPLC ‘A’ procedure differed from the original published method as follows: after samples were 
loaded, the column was washed with 0.5 CV elution buffer A, before a gradient wash down with 
gradually increased mixing percentage of elution buffer B (volume of elution buffer B / volume 
of column wash (%)) began.  The start concentration of elution buffer B (80 % (v/v) acetonitril in 
distilled water) was 0 (v/v) % and the target concentration of elution buffer B was 30 (v/v) % 
with the length of gradient of 3 CV and the gradient delay of 5 CV.  
 
The improved HPLC B procedure 17. Our improved HPLC B procedure was similar to the 
HPLC A procedure, except that the elution buffer A was changed to 8 % methanol (v/v), 20 mM 
acetic acid, adjusted to pH 4.75 with ammonium.  
 
ESI- MS. ESI-MS analysis was performed with LCMS (LCQ, Thermo-Finnigan, U.S.A) at the 
Chemical, Molecular and Materials Analysis Centre, National University of Singapore. Samples 
were directly loaded into the ion source by syringe pump with a flow rate of 3 µl / min. The 
capillary temperature was about 200 ℃. 
 Spectrometric scanning. Spectrometric analysis was performed by measuring the separate 
absorbance (scanning from 250 to 700 nm wavelength, with 2 nm steps) using spectrophotometer 
SpectraMAX 250 with software SOFTmax PRO 4.3 LS. 
 
Data analysis. The HPLC chromatogram was analyzed and exported from Software UNICON 
4.11. Statistical analyses were conducted using one- or two-way ANOVA followed by post hoc 
Student’s t test using software Minitab 14. Graphs were constructed with the software SigmaPlot 
2001.  
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Figure 1 GSH concentration dependent conjugates formation between GSH and DA-derived 
quinones, demonstrated in HPLC A chromatogram 
 (a – f), 1 mM DA was catalyzed with 200 unit tyrosinase in 1 ml distilled water in the presence of 
0.2 – 8 mM GSH for 20 min at 37 °C. Peaks for DA, AM and various GSH-DA quinones 
conjugates were visualized in chromatogram. (a), 0 mM GSH; (b), 0.2 mM GSH; (c), 0.5 mM 
GSH; (d), 1 mM GSH; (e), 2 mM GSH; (f) 8 mM GSH. 
 
(g – l), Changes in peak areas of respective peaks after 1 mM DA was catalyzed with 0 - 200 unit 
tyrosinase in 1 ml distilled water in the presence of 0.2 – 8 mM GSH for 20 min at 37 °C. 
Changes in peak areas of DA (g, *, at least P < 0.05, compared with peak areas of DA catalyzed 
in the same unit of tyrosinase but in the absence of GSH), AM (h), p1 (i), p2 (j), p3 (k) and p4 (l) 
vs GSH concentration are illustrated.  
 
(m). Spectrometric scanning of AM and GSH-DA quinones conjugates p3 and p4 collected from 
HPLC A analysis. 
 
Figure 2 Reaction time dependent conjugates formation between GSH and DA-derived quinones, 
demonstrated in HPLC A chromatogram 
 
(a – f), 1 mM DA was catalyzed with 200 unit tyrosinase in 1 ml distilled water in the presence of 
1 mM GSH for 0 – 240 min at 37 °C.  Peaks for DA, AM and various GSH-DA quinones 
conjugates were visualized in HPLC chromatogram. 
 
(g – l), Peak area changes of respective peaks after different time reactions. 1 mM DA was 
catalyzed with 200 unit tyrosinase in 1 ml distilled water in the presence of 0 - 2 mM GSH for 0 – 
240 min at 37 °C. Changes of peak areas of DA (g, *, at least P < 0.05, compared with peak areas 
of DA catalyzed for same time duration (20, 30 and 240 min time point) but in the absence of 
GSH)), AM (h), p1 (i), p2 (j), p3 (k) and p4 (l) dependent on incubation time were demonstrated.  
 
Figure 3 Conjugates formation between GSH and DA-derived quinones could be influenced by 
reductants (AA and NADPH), demonstrated in HPLC A chromatogram 
 
(a – c), 1 mM DA was catalyzed with 200 unit tyrosinase in 1 ml distilled water in the presence of 
0.8 mM GSH with or without 0 – 10 mM AA or NADPH for 20 min at 37 °C.  Peaks for DA, 
AM, AA and various GSH-DA quinones conjugates were visualized in HPLC 
chromatogram, (a), without AA or NADPH; (b), with 1 mM AA; (c), with 1 mM 
NADPH.  
(d), HPLC chromatogram of 1 mM AA only analyzed by HPLC A procedure.  
(e), HPLC chromatogram of 1 mM NADPH only analyzed by HPLC A procedure. 
 
(f – i), Changes in peak areas of DA (f), AM (g), p3 (h) and p4 (i) vs AA concentration 
were illustrated, *, at least P < 0.05, compared with peak areas in the presence of same 
concentration of GSH but in the absence of AA 
 
(j – m), Changes in peak areas of DA (j), AM (k), p3 (l) and p4 (m) vs NADPH 
concentration were illustrated, *, at least P < 0.05, compared with peak areas in the 
presence of same concentration of GSH but in the absence of NADPH 
 
Figure 4 Formation of different GSH conjugates after aeration with or without oxygen or 
nitrogen gas. 
 After distilled water was aerated with or without gas of oxygen or nitrogen for at least 15 
min, 1 mM DA was then catalyzed with 200 unit tyrosinase in the presence of 0.5 mM 
GSH for 20 min at 37 °C in 1 ml water and analyzed by HPLC A procedure analysis. 
Peaks for DA, AM and various GSH-DA quinones conjugates were visualized in HPLC 
chromatogram (a – c). (a), incubation in distilled water without oxygen or nitrogen 
aeration; (b), in distilled water aerated with oxygen; (c), in distilled water aerated with 
nitrogen;  
(d), change of respective peak areas in HPLC chromatogram after DA, GSH and 
tyrosinase were incubation in distilled water aerated with or without oxygen or nitrogen 
for 20 min at 37 °C. Respective peak areas in HPLC chromatogram after incubation in 
water without oxygen or nitrogen aeration were as respective controls, *, at least P < 0.05, 
compared with respective controls; #, at least P < 0.05, compared with respective peak 
areas after incubation in water aerated with oxygen;  
 
Figure 5 Tandem HPLC-ESI-MS analysis of GSH-DA-quinones conjugates p2 and p4 
 
1 mM DA was catalyzed with 200 unit tyrosinase in 1 ml distilled water in the presence 
of 1.5 mM GSH for 30 min at 37 °C (a). Peaks for p2 and p4 were collected from HPLC 
running. 
(b), p2 collected were adjusted to pH about 8.0 and incubated 3 hrs at 37 °C and then 
analyzed by HPLC A procedure again;  
(c), p2 collected were further separated by HPLC B procedure. Peaks from HPLC B 
procedure were further analyzed by ESI-MS.  
(d), p4 collected were further separated by HPLC B procedure. Peaks from HPLC B 
procedure were further analyzed by ESI-MS.  
(e), p4 collected were adjusted to pH about 8.0 and incubated 3 hrs at 37 °C and then 
analyzed by HPLC A procedure again. 
(f and g), ESI-MS spectrum of GSH conjugates p2 (f) and p4 (g). 
 
Figure 6 p3 could re-arrange to form p6 and could further conjugate with GSH to form 
p5, while AM could conjugate with GSH to form p6 and p7. Tandem HPLC-ESI-MS 
analysis of p3, p5, p6 and p7 
 
1 mM DA was catalyzed with 200 unit tyrosinase in 1 ml distilled water in the presence 
of 0.5 mM GSH for 30 min at 37 °C (a). Peaks for p3 and AM were collected from HPLC 
running.  
(b, e, f), p3 was collected and further incubated at 37 °C 20 min (b), 3 hrs (e) or adjust pH 
to about 8.0 and further incubated at 37 °C overnight (f). After incubation, samples were 
analyzed by HPLC A procedure again. New peak of conjugate p6 could be visualized in 
HPLC A chromatogram. 
 (c), p3 was collected and incubated with 2 mM GSH at 37 °C 3 hrs, samples were 
analyzed by HPLC A procedure again and new GSH conjugates p5 were visualized in 
HPLC chromatogram.  
(d), AM was collected and incubated with 5 mM GSH at 37 °C 3 hrs, samples were 
analyzed by HPLC A procedure again and new GSH conjugates p6 and p7 were 
visualized in HPLC chromatogram.  
(g), new GSH conjugates p6 and p7 were mixed together and rerun by HPLC A 
procedure.  Both p6 and p7 were visualized in HPLC chromatogram. 
(h – k), Tandem HPLC-ESI-MS analysis of GSH-DA-quinones conjugates. p3, p5, p6 
and p7 collected from HPLC A procedure were analyzed by HPLC B procedure.  Peaks 
were re-collected from HPLC B procedure and analyzed by ESI-MS. (h – k), MS- ESI 
spectrum of GSH conjugates p3 (h); p5 (i); p6 (j) and p7 (k). 
 
Figure 7 GSH conjugates formation between GSH and DA derived quinones 
Oxidation of DA could produce DA-o-quinone, which could cyclize spontaneously to 
form AM in the absence of GSH. In the presence of GSH, GSH could conjugate with 
DA-o-quinone to form intermediate GSH conjugates 5-S-GSH-DA-o-quinone (more 
amount) and 2-S-GSH-DA-o-quinone (less amount). The intermediate GSH conjugates 
were unstable and could be reduced to 5-S-GSH-DA (more amount) and 2-S-GSH-DA 
(less amount) under sufficient reductive force. Under insufficient reductive force the 
intermediate GSH conjugates could cyclize spontaneously to form reactive 7-S-GSH-AM 
(more amount) and 4-S-GSH-AM (less amount).  In our current study, 4-S-GSH-AM was 
not detected. These reactive cyclized GSH conjugates could spontaneously transform to 
non-reactive 7-S-GSH-5,6-dihydroxyindole (more) or 4-S-GSH-5,6-dihydroxyindole 
(less).  The reactive 7-S-GSH-AM could further react with GSH to form 4,7-bi-S-GSH-
5,6-dihydroxyindole. On the other hand, cyclized AM could react with GSH to form 4-S-
GSH-5,6-dihydroxyindole (more), 4,7-bi-S-GSH-5,6-dihydroxyindole (middle) and 7-S-
GSH-5,6-dihydroxyindole (less).  GSH conjugates could all polymerize, especially for 
AM and GSH-AM. 
 
Figure 8 Two detrimental positive feedback loops contributing to decreased GSH level in 
the brain and consequently PD onset and development 
Accelerated DA oxidation could be triggered by pathological factors such as iron 
accumulation. The accelerated DA oxidation could produce DA quinones which could 
conjugate with GSH leading to irreversible depletion of GSH and finally decreased GSH 
level in the brain. The decreased GSH level will lead to reactive GSH conjugates 
formation (7-S-GSH-AM) which could further react with GSH. This will lead to 
decreased GSH detoxification efficiency against DA quinones; accelerated GSH 
consumption and further aggravated decrease of GSH level (refer to the lower detrimental 
positive feedback loop). On the other hand, the decreased GSH level will favor DA 
oxidation and contribute to increased oxidative stress and DA quinones production (refer 
to the upper detrimental positive feedback loop). The ROS produced from DA oxidation 
will deplete endogenous reductants and favor reactive GSH conjugates formation. These 
effects will lead to an imbalance between DA toxicity and GSH protective capacity and 
finally account for dopaminergic neuron degeneration and PD onset.  Strategies to elevate 
GSH level could directly stop the detrimental feedbacks.  For example, GSH substitutes 
could be administered to conjugate with DA quinones and thus preserving GSH and help 
to elevate its level in the cells; or exogenous reductants could reduce the intermediate 
GSH conjugates to form non-reactive GSH conjugates and thereby help to break the 
vicious cycle due to the detrimental positive feedbacks.  








